The small-cap sector struggled to keep its head above water along with the rest of the market Wednesday despite good news from names like
Beacon, which makes products to support electricity-grid operation, said it will now order the rest of the materials necessary to build its first 10 commercial flywheel units, having successfully completed "all critical performance tests" on its Smart Energy 25 flywheel. Shares of the Wilmington, Mass., company leapt 15.2% to $1.89.
, meanwhile, licensed its Medusa delivery technology to drugmaking giant
for development of a marketed protein. Medusa is designed to deliver controlled-release formulations of therapeutic proteins and other molecules without reduction in bioactivity.
Flamel shares spiked 86 cents, or 9.4%, to $10; Wyeth recently slipped 1.5% to $45.60.
Elsewhere in the health-care sector, an Oppenheimer analyst said
proposed drug for short bowel syndrome, Gattex, shows strong promise and would play to a largely underserved market. He began coverage of the New Jersey-based with a buy rating, after which shares jumped 14.2% to $4.69.
, based in Mountain View, Calif., boosted its prior sales outlook for the fiscal fourth quarter to between $9.5 million and $10.5 million. That's at least $500,000 higher than the only analyst's estimate, as per Thomson Financial. Shares ratcheted up 13.7% to $7.32.